HC Wainwright Reiterates Buy Rating on Structure Therapeutics Inc. (GPCR)
HC Wainwright maintains its buy rating on Structure Therapeutics with a $70 price target.
Key Points
- HC Wainwright reiterated its buy rating on Structure Therapeutics, setting a price target of $70 on June 11, 2026.
- Shares of NasdaqGM:GPCR are trading around $43.24, with a market cap of $3.05 billion and a forward P/E ratio not meaningful due to lack of profitability.
- Insider buying activity includes COO Matthew Lang purchasing shares on April 15, 2026, while analysts maintain a strong buy consensus.
HC Wainwright has reiterated its buy rating on Structure Therapeutics Inc. (NASDAQ: GPCR), setting a price target of $70. This update came on June 11, 2026, as the firm's analyst Ananda Ghosh expressed continued confidence in the company's prospects.
Structure Therapeutics Stock Snapshot
Shares of Structure Therapeutics, listed on NasdaqGM under the ticker GPCR, are currently trading around $43.24. The company has a market capitalization of approximately $3.05 billion. While it does not have a meaningful P/E ratio due to negative earnings, the company's forward P/E ratio is also not applicable. Structure Therapeutics has a beta of -1.423, indicating less volatility compared to the market. The stock's 52-week range spans from a low of $15.80 to a high of $94.90, with a 50-day moving average of $43.50 and a 200-day moving average of $47.72. The company maintains a strong liquidity position with a current ratio of 24.81 and a quick ratio of 24.43, alongside a low debt-to-equity ratio of 0.428.
Insider Buying and Selling at Structure Therapeutics Inc.
Recent insider activity at Structure Therapeutics includes several purchases. On April 15, 2026, Matthew Lang, the company's COO and GC, acquired 184,614 shares. Earlier, on March 19, 2026, CEO Raymond Stevens bought 260,217 shares, and Chief Scientific Officer Xichen Lin purchased 53,703 shares. These transactions suggest some insiders are increasing their stakes in the company.
Analysts Set New Price Targets
On June 11, 2026, HC Wainwright & Co. maintained its buy rating on Structure Therapeutics with a price target of $70. Earlier, on April 27, 2026, Canaccord Genuity initiated coverage with a buy rating and a $101 target. The consensus among analysts remains bullish, with a strong buy recommendation and an average target price of $104.59 based on 16 analyst opinions.
About Structure Therapeutics
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California. It focuses on developing novel oral small molecule therapeutics for chronic diseases with unmet medical needs. The company's lead product, GSBR-1290, is in phase 2 trials for treating obesity and related conditions. Other pipeline projects include treatments for idiopathic pulmonary fibrosis and obesity-related disorders. Led by CEO Dr. Raymond C. Stevens, the company employs around 220 people.
Bottom Line
HC Wainwright's reiterated buy rating for Structure Therapeutics reflects ongoing confidence in its growth potential. Investors track such analyst updates closely, though it's important to remember that these ratings are based on past performance and projections. As always, 13F filings and analyst opinions offer insights into potential trends but do not guarantee future results.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.